Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients ...

Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Alvotech is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Nail changes can reveal hidden health issues long before other symptoms appear. Here's what to watch for and why it matters.

Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements ...

MoonLake Immunotherapeutics has secured up to $500 million in non-dilutive financing from Hercules Capital, bolstering its ...